Robert Debernardo, MD
Gynecologic Oncology · Cleveland, OHNPI 1891728309
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (55.7%), food and beverage and education — rather than concentrated in one kind of arrangement. Medtronic accounts for 80.9% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $1,119 and has fallen 82.8% since, to $193 in 2024. That places this record below the midpoint for gynecologic oncology clinicians in OH, where the typical reported total is $1,215.
Across 22 payments — averaging $75.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Tesaro, Inc.$128
- Clovis Oncology, Inc.$79
- Merck$43
- AstraZeneca$40
- GSK$26
Across 7 payments — averaging $2107.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$15K
What the payments were for
- Travel & lodging$92056%
- Food & beverage$70443%
- Education$262%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 14 | $1,335 |
| Tesaro, Inc. | 2 | $128 |
| Clovis Oncology, Inc. | 3 | $79 |
| Merck | 1 | $43 |
| AstraZeneca | 1 | $40 |
| GSK | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,651 in reported general payments places this provider in the 50th percentile of 62 gynecologic oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Everolimus | 22 | $82,638 |
| Letrozole | 16 | $238 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Cleveland
- Amelia JerniganCleveland$85K
- Kimberly ResnickCleveland$29K
- Peter RoseCleveland$4K
- Kevin EliasCleveland$4K
- Chad MichenerCleveland$3K
- Mariam Al HilliCleveland$2K
- Anthony RizzoCleveland$1K
- Lisa Rauh-BenoitCleveland$930
- Roberto VargasCleveland$482
- Lindsay FergusonCleveland$467
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.